Navigation Links
Amarin Corporation to Host Investor Conference Call on Wednesday, November 10, 2010
Date:11/9/2010

DUBLIN and MYSTIC, Conn., Nov. 9, 2010 /PRNewswire-FirstCall/ -- Amarin Corporation plc (Nasdaq: AMRN) has scheduled a conference call for Wednesday, November 10, 2010 at 11:00 am Eastern Time (4:00 pm UTC/GMT) to discuss selected financial and operating results from the third quarter, including a progress update of the Company's MARINE and ANCHOR trials, the two pivotal Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels in separate patient populations.

The conference call may be heard live via the investor relations section of the Company's website at www.amarincorp.com and will also be available by dialing the following numbers:From outside U.S. dial-in:

(201) 689-8565 From inside U.S. dial-in:

(877) 407-0778Replay will be made available for a period of two weeks following the conference calls. To hear a replay of the call dial 1-201-612-7415 (outside U.S.) 1-877-660-6853 (inside U.S.). For both dial in numbers please use account number is 286 and conference id 359371.

About AmarinAmarin Corporation plc is a clinical-stage biopharmaceutical company with expertise in lipid science focused the treatment of cardiovascular disease. The Company's lead product candidate is AMR101 (ethyl icosapentate), which is presently being investigated in two Phase 3 clinical trials, one for the treatment of patients with very high triglyceride levels and the other for the treatment of patients with high triglycerides with mixed dyslipidemia. Both of these Phase 3 trials are conducted under Special Protocol Assessment (SPA) agreements with the U.S. Food and Drug Administration (FDA). Amarin also has next-generation lipid candidates under evaluation for preclinical development. For more information please visit www.amarincorp.com.

Contacts:Investor Contact Information: John F. TheroChief Financial OfficerIn US: +1 (860) 572 4979 investor.relations@amarincorp.comLee M. SternThe Trout GroupIn U.S. +1 (646) 378-2922lstern@troutgroup.comInternational Media Contact Information: Mark Swallow or David DibleCitigate Dewe RogersonIn UK: +44 (0)207 638 9571mark.swallow@citigatedr.co.uk
'/>"/>

SOURCE Amarin Corporation plc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarin to Present at UBS Life Sciences Conference
2. Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer
3. Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia
4. Baxa Corporation Introduces ExactaMix™ 1200 Automated Compounder for Sterile, Multi-Ingredient Solutions
5. United American Healthcare Corporation Announces Senior Management Appointments and Relocation to Chicago
6. Luminex Corporation Reports Third Quarter 2010 Results
7. Gentris Corporation Names New Chief Scientific Advisor
8. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
9. DURECT Corporation Announces Third Quarter 2010 Financial Results
10. Techne Corporation Declares Dividend
11. Pharmos Corporation Reports 2010 Third Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Pharma To Market Pty Ltd and Ador Consulting Pte Ltd announce ... of Pharma To Market Pte Ltd, based in Singapore ... their expansion into Asia with the opening ... are delighted to appoint Joelle Chia , former owner of ... based entity. Joelle brings with her an extensive business network throughout ...
(Date:2/24/2017)... YORK , Feb. 23, 2017  The ... 330.6 million by 2021 from USD 275.9 million ... Read the full report: http://www.reportlinker.com/p04718602-summary/view-report.html ... increasing spending on pharmaceutical R&D, and growth in ... driving the market growth for particle counters. On ...
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... Prophecy concerning this present generation. Yisrayl makes an astounding statement when he says ... He explains that the Bible details the current times so plainly that anyone should ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... will return to the La Gorce Country Club in Miami Beach to host ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... in thought leadership , media relations, content marketing, social media management, corporate ... several clients already in the state and in nearby New Hampshire, Massachusetts and ...
(Date:2/23/2017)... ... 23, 2017 , ... ERT, a global data and technology ... Research, a leading clinical development service provider, has selected ERT’s Trial Oversight suite ... in part to an array of circumstances including the use of multiple data ...
Breaking Medicine News(10 mins):